Bioreactors and Fermenters market to reach US $4461 million by 2024
The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report...
List view / Grid view
The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report...
1 March 2017 | By Dorothea Wenzel, Senior VP Global Business Franchise Fertility, Merck
We caught up with Merck's Dorothea Wenzel to hear all about the latest in fertility treatments, training and technologies and to find out the truth about infertility...
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
7 December 2015 | By Victoria White
Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials...
1 December 2015 | By Victoria White
An official decision on the Ophran Drug Designation is expected from the European Commission in December...
18 November 2015 | By Victoria White
Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody...
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
12 May 2015 | By Victoria White
The FDA has granted Fast Track designation for the development of evofosfamide for the treatment of patients with advanced pancreatic cancer...
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
23 March 2015 | By Victoria White
Merck is fighting schistosomiasis in Mozambique, providing WHO with praziquantel tablets free of charge and presenting 20,000 educational brochures...
12 December 2014 | By Merck KGaA
Merck supports the World Health Organization (WHO) to fight the parasitic worm disease schistosomiasis in Africa...